Bromocriptine for drug-resistant advanced prostate cancer in adults
Official title: RESEARCH PROJECT 1: DAQING WU
Funded at Clark Atlanta University · NIH-11325044 · Data updated 2026-11-12
A cancer research project tests whether the already-approved drug bromocriptine can help adults with advanced, chemotherapy-resistant prostate cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Clark Atlanta University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | June 1, 1997 |
| Project end | March 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $187,957 |
| NIH project number | 5U54MD007590-39 |
| Project ID | NIH-11325044 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with metastatic castration-resistant prostate cancer whose disease does not respond to standard chemotherapy.
✕Less likely to help
Patients without chemoresistant disease or those unable to take bromocriptine safely may not benefit.
What this research studies
This project uses a new screen to study how bromocriptine works against cancer cells that no longer respond to standard chemotherapy. It will test how the drug stops cancer cell growth and promotes cell death, including both ways the drug works via dopamine receptors and other pathways. It also plans to evaluate whether oral bromocriptine can effectively reach tumors and slow disease in preclinical models. The study aims to build solid evidence that bromocriptine could be a safe, affordable option for patients with this tough-to-treat cancer.
Why it matters
Potential benefit: If successful, bromocriptine could become an affordable therapy for patients with chemoresistant prostate cancer.
How similar studies have gone: Preliminary data show bromocriptine inhibits chemoresistant prostate cancer cells and shrinks tumors in mouse models, suggesting potential translational impact.
Where this research is happening
-
Clark Atlanta University
Atlanta, United States Active
Researchers
- Principal investigator: Wu, Daqing — Clark Atlanta University
- Study coordinator: Wu, Daqing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.